Independent pharmacies are usually financed with an SBA 7(a) loan at roughly 10–20% down — the program fits because the value is mostly the prescription file, inventory, and goodwill rather than hard collateral. Lenders who know pharmacy normalize cash flow for PBM reimbursement and DIR fees, value the script base and payer mix, and often pair the acquisition loan with a line of credit to cover insurance receivables and drug inventory. The same structure works for a de novo (startup) pharmacy or a partner buy-in.
Buying or starting an independent pharmacy is a financing problem built around intangibles: a prescription file, a payer mix, and a margin structure that's squeezed by the PBMs. The SBA funds these deals regularly, but the underwriting looks different from a typical retail acquisition. Here's how it works for an acquisition, a startup, or a partner buy-in.
The Prescription File Is the Asset
The core value of an independent pharmacy is its prescription file — the script count, refill base, and the payer mix behind it. Lenders and buyers underwrite on prescription volume, gross profit per script, and how durable the patient base is. Watch for concentration: a pharmacy leaning on one nursing-home contract or a single 340B relationship carries more risk than a broad retail base. Because the deal is mostly intangible value plus inventory, this is squarely SBA 7(a) territory — a conventional bank rarely lends against a script file.
PBM & DIR Margin Pressure
Pharmacy margins are pressured by PBM reimbursement and DIR (direct and indirect remuneration) fees that can pull back margin after a script is already filled. A lender who finances pharmacies builds this into the cash-flow analysis — they want gross margin per script and payer mix, not just revenue. A buyer who can articulate a plan to offset that pressure (front-end retail sales, immunizations and clinical services, adherence/med-sync programs, compounding) presents a materially stronger file.
Financing Options
| Option | Best for | Typical down payment |
|---|---|---|
| SBA 7(a) | Acquisition, de novo startup, or partner buy-in (script file + inventory + goodwill, up to $5M) | 10–20% |
| SBA 504 | When you're also buying the building | ~10–15% |
| Line of credit / AR facility | Insurance receivables & drug inventory working capital | n/a (revolving) |
| Equipment loan | Robotics/automation, compounding equipment, POS/IT | 0–15% |
For acquisitions and partner buy-ins, see using an SBA loan to buy a business.
Insurance AR & Inventory
- Insurance receivables: a large share of revenue sits in third-party AR between filling a script and getting paid. A line of credit or AR facility bridges that gap so payroll and inventory buying never stall.
- Drug inventory is sizable and turns; it's valued at acquisition and replenished through working capital.
- Compliance: DEA registration, state board licensure, and controlled-substance recordkeeping are confirmed as part of closing.
What Lenders Check
- Script volume & gross margin per script, plus payer-mix concentration.
- Normalized cash flow net of DIR/PBM clawbacks; DSCR ~1.20x+.
- Buyer credentials — typically a licensed pharmacist or strong pharmacy management on the team.
- Clean licensure/DEA and a realistic transition plan to retain patients.
- Growth levers — front-end, clinical services, adherence programs.
See what lenders look for in an SBA loan.
Next Step
Whether you're buying an established independent, opening a de novo store, or buying out a partner, the right structure pairs an SBA 7(a) acquisition loan with working capital for AR and inventory. Get matched with pharmacy lenders who understand script-file valuation and reimbursement pressure.
Worked Example: Acquiring an Independent Pharmacy
Consider a pharmacist buying an independent pharmacy for $800,000. Much of that price is goodwill tied to the patient base and the prescription files — the recurring scripts that walk in the door every month — plus inventory. SBA 7(a) financing suits this acquisition because the value is largely intangible (the Rx file and patient relationships) rather than hard collateral, and the SBA guarantee gives the lender comfort to lend against it. A licensed pharmacist-buyer with operating experience presents a strong file.
The diligence centers on reimbursement and concentration. Independent pharmacies live and die by their payer mix and pharmacy-benefit-manager (PBM) reimbursement, which can compress margins, so lenders examine prescription volume, payer mix, and trends closely. They also weigh dependence on a single nearby prescriber or facility — lose that referral source and the script count drops. A buyer who documents stable script volume, a diversified payer and prescriber base, and a transition plan with the selling pharmacist strengthens the application considerably.
What SBA Lenders Weigh on a Pharmacy
- Prescription volume and trend — the recurring scripts that drive revenue.
- Payer mix and reimbursement — PBM and insurance dynamics that set the real margin.
- Prescriber concentration — diversification beyond a single referral source.
- Inventory and Rx file value — the tangible and intangible assets being purchased.
- Buyer licensing and experience — a licensed pharmacist with operating background.
Frequently Asked Questions
What down payment do you need to buy a pharmacy?
Usually 10–20% down with an SBA 7(a) loan. Independent pharmacy acquisitions are goodwill- and prescription-file-heavy, so lenders that know the space lend on the script base and cash flow, but a pharmacist-buyer with strong credit and industry experience is expected. First-time-owner startups (de novo pharmacies) typically need more equity and a detailed ramp plan.
How is an independent pharmacy valued for a loan?
The core asset is the prescription file — the script count, refill base, and payer mix — plus inventory and goodwill. Lenders and buyers look at prescription volume, gross profit per script, and how durable the patient base is (a few large nursing-home or 340B contracts can be a concentration risk). Drug inventory is sizable but turns, and it's valued at acquisition. The deal is mostly intangible value, which is why SBA financing — not conventional — is the norm.
How do PBM reimbursement and DIR fees affect financing?
Pharmacy margins are pressured by PBM reimbursement and DIR (direct and indirect remuneration) fees, which can claw back margin well after a script is filled. Lenders who finance pharmacies understand this and normalize cash flow accordingly — they want to see gross margin per script and the payer mix, not just top-line revenue. A buyer who can show a plan to grow front-end sales, clinical services, or adherence programs presents a stronger file.
Can you finance pharmacy insurance receivables (AR) and inventory?
Yes. Pharmacies carry significant third-party insurance receivables (the gap between filling a script and getting paid by the PBM/insurer) and a large drug inventory, so a line of credit or working-capital facility alongside the acquisition loan smooths cash flow. AR-based financing is common for pharmacies specifically because so much revenue sits in insurance receivables at any moment.